The oncology-focused biopharmaceutical company uses its proprietary probody technology platform to create cancer immunotherapies against clinically-validated targets. Their Probody therapeutics are designed to enhance tumor-targeting features of an antibody and reduce drug activity in healthy tissues. CytomX Therapeutics is committed to transforming cancer treatment with their novel Probody therapeutic platform and has a broad pipeline comprised of five clinical-stage programs, with even more in development. The company values diversity, equity, and inclusion and strives to maintain a culture that encourages individuals to be themselves, feel involved, respected, and connected.